Bionano Genomics (BNGO) Set to Announce Earnings on Thursday
Bionano Genomics (BNGO) Set to Announce Earnings on Thursday
Bionano Genomics (NASDAQ:BNGO) will be posting its quarterly earnings results after the market closes on Thursday, March 9th. Analysts expect Bionano Genomics to post earnings of ($0.09) per share for the quarter. Individual that wish to register for the company's earnings conference call can do so using this link.
比奧納諾基因（NASDAQ：BNGO）將於 3 月 9 日（週四）收市後公佈其季度收益業績。分析師預計，比奧納諾基因組學將在本季度發布每股收益（0.09 美元）。希望註冊公司盈利電話會議的個人可以使用此鏈接進行註冊。
Bionano Genomics Stock Performance
比昂諾基因組學股票表現
Bionano Genomics stock opened at $1.35 on Tuesday. The business has a 50 day moving average of $1.61 and a 200-day moving average of $1.98. Bionano Genomics has a 1 year low of $1.16 and a 1 year high of $4.35. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.51 and a quick ratio of 5.77. The company has a market capitalization of $400.84 million, a P/E ratio of -3.29 and a beta of 2.30.
比奧納諾基因股票週二開盤 1.35 美元。該業務的 50 日移動平均線為 1.61 美元，200 天移動平均線為 1.98 美元。比奧納諾基因組學的 1 年低點為 1.16 美元，創下 1 年高點 4.35 美元。該公司的債務與權益比率為 0.01，流動比率為 6.51，快速比率為 5.77。該公司的市值為 400.84 億美元，市盈率為 -3.29，測試版為 2.30。
Wall Street Analyst Weigh In
華爾街分析師稱重
BNGO has been the topic of several analyst reports. BTIG Research reiterated a "buy" rating and issued a $3.50 target price on shares of Bionano Genomics in a report on Monday, December 12th. Oppenheimer cut their price target on Bionano Genomics from $12.00 to $9.00 and set an "outperform" rating on the stock in a report on Monday, February 6th. Finally, Scotiabank started coverage on Bionano Genomics in a report on Wednesday, January 4th. They set a "sector outperform" rating and a $4.00 price target on the stock.
BNGO 一直是幾個分析師報告的主題。BTIG 研究在 12 月 12 日星期一的一份報告中重申了「買入」評級，並發布了 Bioano 基因組學股票的目標價 3.50 美元。奧本海默將其對比奧納諾基因組學的價格目標從 12.00 美元降至 9.00 美元，並在 2 月 6 日（星期一）的一份報告中設定了該股票的「表現超越」評級。最後，豐業銀行在 1 月 4 日（週三）的一份報告中開始對生物諾基因組學的報導。他們設定了「行業跑贏」評級和 $4.00 的股票價格目標。
Institutional Investors Weigh In On Bionano Genomics
機構投資者權衡生物基因組學
Several large investors have recently made changes to their positions in the business. Virtu Financial LLC increased its position in shares of Bionano Genomics by 299.2% during the 4th quarter. Virtu Financial LLC now owns 258,591 shares of the company's stock valued at $378,000 after purchasing an additional 193,819 shares during the last quarter. Verition Fund Management LLC bought a new position in shares of Bionano Genomics during the 4th quarter worth $44,000. Alpine Global Management LLC grew its stake in shares of Bionano Genomics by 242.6% during the 4th quarter. Alpine Global Management LLC now owns 54,477 shares of the company's stock worth $80,000 after acquiring an additional 38,577 shares during the period. Engineers Gate Manager LP bought a new position in shares of Bionano Genomics during the 4th quarter worth $73,000. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Bionano Genomics by 3.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,199,429 shares of the company's stock worth $3,211,000 after acquiring an additional 79,801 shares during the period. 26.91% of the stock is owned by hedge funds and other institutional investors.
一些大型投資者最近更改了他們在業務中的位置。Virtu 金融有限責任公司在第四季度增加了 299.2％ 在比奧納諾基因組學的股份地位。在上一季度額外購買 193,819 股股票後，維圖金融有限責任公司現在擁有該公司 258,591 股價值 378,000 美元的股票。驗證基金管理有限責任公司在第四季度期間購買了 BIONANO 基因組學股份的新位置，價值 44,000 美元。阿爾派全球管理有限責任公司在第四季度增長了 242.6％ 的比奧納諾基因組學股份的股份。在此期間，阿爾派環球管理有限責任公司現在擁有該公司股票的 54,477 股，價值 80,000 美元。工程師門經理 LP 在第四季度期間購買了比奧納諾基因組學股份的新位置，價值 73,000 美元。最後，查爾斯嘉信投資管理有限公司在第四季度增加了 3.8％ 的比奧納諾基因組學股份的股份。嘉信理財投資管理股份有限公司現時擁有該公司股票 2,199,429 股價值 3,211,000 美元的股份。26.91% 的股票由對沖基金和其他機構投資者擁有。
Bionano Genomics Company Profile
比奧納諾基因組學公司簡介
Bionano Genomics, Inc is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics.
Bionano 基因組學, Inc 是一家生命科學儀器公司，專注於基因組分析空間。該公司致力於 Saphyr 系統的開發和營銷，Saphyr 系統是一個用於超敏感和超特異性結構變異檢測的平台，使研究人員和臨床醫生能夠加速尋找新的診斷和治療靶標，並簡化細胞遺傳學。